Insulin-like Growth Factor Axis Gene Polymorphisms and Clinical Outcomes in Pancreatic Cancer

Overview

Journal Gastroenterology

Specialty Gastroenterology

Date 2010 Apr 27

PMID 20416304

Citations 33

Authors

Xiaoqun Dong

Milind Javle

Kenneth R Hess

Rachna Shroff

James L Abbruzzese

Donghui Li

Affiliations

Soon will be listed here.

Abstract

Background & Aims: Insulin-like growth factor (IGF)-axis mediated signaling pathways play an important role in pancreatic cancer development and progression. We examined whether IGF-axis gene variants are associated with clinical outcomes in pancreatic cancer.

Methods: We retrospectively genotyped 41 single-nucleotide polymorphisms from 10 IGF-axis genes in 333 patients with localized pancreatic adenocarcinoma and validated the findings in 373 patients with advanced disease. Associations between genotype and overall survival (OS) were evaluated using multivariable Cox proportional hazard regression models.

Results: IGF1 *8470T>C, IGF1R IVS2+46329T>C, IGFBP3 A32G, IRS1 G972R in patients with localized disease; IGF1R IVS20-3431A>G, IGF1R T766T, IGFBP3-202A>C, IRS1 IVS1+4315C>G, IRS1 G972R in patients with advanced disease; and IGF1R T766T, IGF2R L252V, IGFBP3 -202A>C, IRS1 IVS1+4315C>G, IRS1 G972R, IRS2 IVS1+5687T>C in all patients were significantly associated with OS (P<or=.007). Two haplotypes containing the variant allele of either IRS1 G972R or IVS1-10949G>A, and an IRS2 haplotype predicted worse OS (P<or=.002). A significant correlation between increased number of unfavorable genotypes and decreased OS was observed; patients with 0-1 (n=247), 2 (n=237), 3 (n=145), 4 (n=60), and 5-8 (n=17) unfavorable genotypes had median survival time of 24.2, 16.4, 14.4, 9.6, and 7.4 months, respectively (P<.001). Several single-nucleotide polymorphisms of IGF1R, IGF2R, and IRS1 gene were significantly associated with tumor response to therapy and disease stage.

Conclusions: These data suggest that individual genetic variations in the IGF axis pathway may predict worse survival in patients with pancreatic cancer. This information may identify population subgroups that could benefit from IGF(1)R-targeted agents.

Citing Articles

Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial.

Jo J, Kim Y, Choi H, Kim H, Lee H, Choi Y Br J Cancer. 2023; 130(1):43-52.

PMID: 37903909 PMC: 10781743. DOI: 10.1038/s41416-023-02474-w.

Pancreatic Cancer-Secreted Proteins: Targeting Their Functions in Tumor Microenvironment.

Cammarota A, Falco A, Basile A, Molino C, Chetta M, DAngelo G Cancers (Basel). 2023; 15(19).

PMID: 37835519 PMC: 10571538. DOI: 10.3390/cancers15194825.

Drugging IGF-1R in cancer: New insights and emerging opportunities.

Wang P, Mak V, Cheung L Genes Dis. 2023; 10(1):199-211.

PMID: 37013053 PMC: 10066341. DOI: 10.1016/j.gendis.2022.03.002.

The Role of Circulating Protein and Metabolite Biomarkers in the Development of Pancreatic Ductal Adenocarcinoma (PDAC): A Systematic Review and Meta-analysis.

Kumar S, Santos R, McGuigan A, Singh U, Johnson P, Kunzmann A Cancer Epidemiol Biomarkers Prev. 2021; 31(5):1090-1102.

PMID: 34810209 PMC: 9377754. DOI: 10.1158/1055-9965.EPI-21-0616.

Interplay Between Diabetes and Pancreatic Ductal Adenocarcinoma and Insulinoma: The Role of Aging, Genetic Factors, and Obesity.

Duvillie B, Kourdoughli R, Druillennec S, Eychene A, Pouponnot C Front Endocrinol (Lausanne). 2020; 11:563267.

PMID: 33101198 PMC: 7556217. DOI: 10.3389/fendo.2020.563267.

References

Johnson S, Dennis R, Barone G, Lamps L, Haun R . Differential expression of insulin-like growth factor binding protein-5 in pancreatic adenocarcinomas: identification using DNA microarray. Mol Carcinog. 2006; 45(11):814-27. DOI: 10.1002/mc.20203. View

Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S . Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res. 2008; 68(20):8322-32. DOI: 10.1158/0008-5472.CAN-07-6720. View

Pounds S, Morris S . Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. Bioinformatics. 2003; 19(10):1236-42. DOI: 10.1093/bioinformatics/btg148. View

Neid M, Datta K, Stephan S, Khanna I, Pal S, Shaw L . Role of insulin receptor substrates and protein kinase C-zeta in vascular permeability factor/vascular endothelial growth factor expression in pancreatic cancer cells. J Biol Chem. 2003; 279(6):3941-8. DOI: 10.1074/jbc.M303975200. View

Withers D, Burks D, Towery H, Altamuro S, Flint C, White M . Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat Genet. 1999; 23(1):32-40. DOI: 10.1038/12631. View

Patel A, Cheng I, Canzian F, Le Marchand L, Thun M, Berg C . IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One. 2008; 3(7):e2578. PMC: 2440354. DOI: 10.1371/journal.pone.0002578. View

Knowlden J, Jones H, Barrow D, Gee J, Nicholson R, Hutcheson I . Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Res Treat. 2007; 111(1):79-91. DOI: 10.1007/s10549-007-9763-9. View

Sentinelli F, Filippi E, Cavallo M, Romeo S, Fanelli M, Baroni M . The G972R variant of the insulin receptor substrate-1 gene impairs insulin signaling and cell differentiation in 3T3L1 adipocytes; treatment with a PPARgamma agonist restores normal cell signaling and differentiation. J Endocrinol. 2006; 188(2):271-85. DOI: 10.1677/joe.1.06290. View

Dong X, Park S, Lin X, Copps K, Yi X, White M . Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth. J Clin Invest. 2005; 116(1):101-14. PMC: 1319221. DOI: 10.1172/JCI25735. View

10.

Morgan M, Parsels L, Maybaum J, Lawrence T . Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clin Cancer Res. 2008; 14(21):6744-50. PMC: 2697824. DOI: 10.1158/1078-0432.CCR-08-1032. View

11.

McGettrick A, Feener E, Kahn C . Human insulin receptor substrate-1 (IRS-1) polymorphism G972R causes IRS-1 to associate with the insulin receptor and inhibit receptor autophosphorylation. J Biol Chem. 2004; 280(8):6441-6. DOI: 10.1074/jbc.M412300200. View

12.

Porzio O, Federici M, Hribal M, Lauro D, Accili D, Lauro R . The Gly972-->Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells. J Clin Invest. 1999; 104(3):357-64. PMC: 408413. DOI: 10.1172/JCI5870. View

13.

Samani A, Yakar S, LeRoith D, Brodt P . The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2006; 28(1):20-47. DOI: 10.1210/er.2006-0001. View

14.

Pollak M . Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8(12):915-28. DOI: 10.1038/nrc2536. View

15.

Dong X, Jiao L, Li Y, Evans D, Wang H, Hess K . Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J Clin Oncol. 2009; 27(10):1592-9. PMC: 2668967. DOI: 10.1200/JCO.2008.20.1111. View

16.

Schiller H, Szekeres A, Binder B, Stockinger H, Leksa V . Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor. Mol Biol Cell. 2008; 20(3):745-56. PMC: 2633380. DOI: 10.1091/mbc.e08-06-0569. View

17.

Bauer T, Somcio R, Fan F, Liu W, Johnson M, Lesslie D . Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther. 2006; 5(7):1676-82. DOI: 10.1158/1535-7163.MCT-05-0175. View

18.

Chen W, Wang S, Tian T, Bai J, Hu Z, Xu Y . Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur J Hum Genet. 2009; 17(12):1668-75. PMC: 2987015. DOI: 10.1038/ejhg.2009.86. View

19.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

20.

Wolpin B, Michaud D, Giovannucci E, Schernhammer E, Stampfer M, Manson J . Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. Cancer Res. 2007; 67(16):7923-8. DOI: 10.1158/0008-5472.CAN-07-0373. View